Abstract
Esmethadone (dextromethadone; REL-1017) is a novel NMDA channel blocker currently in development for major depressive disorder (MDD). NMDA receptors are known to play a primary role in neural plasticity. An excess of glutamate in the synaptic cleft and impaired neural plasticity have been implicated in the pathogenesis of MDD. The NMDA receptor 1 subunit (NMDAR1) is essential for NMDA receptor membrane expression. To gain insight into the mechanism of action of REL-1017, we examined the effect of glutamate and REL-1017 on the expression of NMDAR1 in ARPE-19 cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
